1969

The Value of Earthworms by Eric Johnson (page 1) Golf Course Bridge Construction by Robert A. Huntley (2) Importance of Trees and Care by Donald Pipczinski (3) Management Practices Help Control Turf Diseases by Larry Bunn (3) Class Will of \u2769 (5) Famous Sayings of \u2769 (6) The Reluctant Human by John Denison (A-1) Communicating by Frank Gallagher (A-4) Vandalism on the Golf Course by Edward B. Patroski (A-7) The GCSAA Organization - What it Means to You (A-13) Role of Potash in Turf Production by Lindsay D. Brown (A-17) Dew is Note Dew by Tom Mascaro (A-28) Insects in Turf and Their Control by John C. Schread (A-36) Turf Treatment and the Balance of Nature by Haim B. Gunner (A-39) The After-Effects of Irrigation by John C. Harper, II (A-40) Athletic Field Specifications by John C. Harper, II (A-45) Pennsylvania Turfgrass Survey by John C. Harper, II (A-52) Seeding Vs. Sodding by Norman Gray (A-54) Synthetic Turf by R. Spencer Thompson (A-58) Why Do We Have Dealers .. Does He Justify His Existence? (A-61) The Importance of Suppliers of Turf materials by John N. Magovern (A-64) Golf Course Maintenance at St. Andrews by John C. Campbell (A-68) Ground Covers for Golf Courses by Jack Eggens (A-75) Gardening - 600 BC to Country Club Road by Warren Bidwell (A-79) Blues Vs. Bents for Fairway Turf by James L. Holmes (A-87

1962

Turf on the Launching Pad (page 1) Turf management Club News (3) Education, Experience and Attitude (4) A Blade of Grass (5) Picture - Professor Lawrence S. Dickinson (6) Picture - Thomas Mascaro - Banquet Speaker (7) Planting Trees on the Golf Course (8) Two-Way Radios (8) Greens Mowing Procedure (9) Watering and Topdressing as Related to Poa annua Infestations (10) Picture - Stockbridge Majors in Turf Management (12) Picture - Graduates of Winter School for Turf Managers - 1962 (13) Review of Season\u27s Pests by Joseph Troll (A-1) Today\u27s Trends in Golf Course Development by Col. Harry C. Eckoff (A-3) Breeding and Selection of Fine Turf Grasses by Dr. B. R. Anderson Penncross Bentgrass by J. Dutch(A-13) Poa annua by Alexander Radko (A-16) Velvet Bent by Jesse DeFrance (A-19) Vegetative Creeping Bentgrasses by Fred Grau (A-21) Modification of SOils for Green Construction & Top Dressing by Prof. H. B. Musser (A-27) Soil COmpaction by Donald Waddington (A-32) Irrigation Practices and the Need of Basic Research by Prof. Edward PIra (A-36) Water Sources by Z. Mills (A-39) Athletic Field Maintenance by Thomas Mascaro (A-41) Planning the Landscape Around the House by Prof. Harold Mosher (A-43

1968

Maintenance of Golf Carts by Thomas Pepe (page 1) Why a Golf Course Superintendent Should Play Golf by Stephen Skowronski (2) Tree Pruning by Martin Walsh (3) Golf Course Labor: A Dilemma by Robert Barber (5) Turf Problems by Alexander M. Radko (A-1) 1967 Turfgrass Problems by Lee Record (A-3) Southern Turfgrass Production and Problems by Ralph W. White Jr. (A-5) Canadian Turf Grass Production and Problems by David Moote (A-8) Turf Research Abroad by C.R. Skogley (A-13) Turf Research at Home by Victor B. Younger (A-14) Turfgrass Research - An Industrial Approach by J. A. Simmons (A-16) Cutting Labor Costs in Turfgrass Managemnt by Tom Mascaro (A-24) The Reluctant human by John W. Denison (A-28) The Problem Drinker - Management Responsibility by G.E. Osburn (A-31) Contemporary Design Standards by Geoffrey S. Cornish (A-34) Construction - Superintendents\u27 Viewpoint by Robert E. Grant (A-36) Construction b Contract and the Role of the Superintendent by David Canavan (A-39) Seed Production by Robert J. Peterson (A-41) Cemetery Turf Maintenance on a High and Low Budget by Stanley Sosenski (A-45) Ten Steps to a Good Lawn by John Zak (A-49) Review of Herbicides for Turf Weed Control by Alvin A. Baber (A-53

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Bridging the gaps in test interpretation of SARS-CoV-2 through Bayesian network modelling

Abstract In the absence of an established gold standard, an understanding of the testing cycle from individual exposure to test outcome report is required to guide the correct interpretation of severe acute respiratory syndrome-coronavirus-2 reverse transcriptase real-time polymerase chain reaction (RT-PCR) results and optimise the testing processes. Bayesian network models have been used within healthcare to bring clarity to complex problems. We use this modelling approach to construct a comprehensive framework for understanding the real-world predictive value of individual RT-PCR results. We elicited knowledge from domain experts to describe the test process through a facilitated group workshop. A preliminary model was derived based on the elicited knowledge, then subsequently refined, parameterised and validated with a second workshop and one-on-one discussions. Causal relationships elicited describe the interactions of pre-testing, specimen collection and laboratory procedures and RT-PCR platform factors, and their impact on the presence and quantity of virus and thus the test result and its interpretation. By setting the input variables as 'evidence' for a given subject and preliminary parameterisation, four scenarios were simulated to demonstrate potential uses of the model. The core value of this model is a deep understanding of the total testing cycle, bridging the gap between a person's true infection status and their test outcome. This model can be adapted to different settings, testing modalities and pathogens, adding much needed nuance to the interpretations of results